MedTrace Logo

Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease

NCT00929734 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2015-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary disease.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Rosuvastatin

10mg tablets, once daily in three months

DRUG

Placebo

1 tablet, once daily in three months

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Haukeland University Hospital

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Torbjørn Omland, PhD · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Norway

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929734 on ClinicalTrials.gov